TA274 Macular oedema (diabetic) - ranibizumab: review decision - April 2015 information
History
A list of downloadable documents created during development.
Background information
-
-
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE decision paper - March 2015
-
-
TA274 Macular oedema (diabetic) - ranibizumab: review proposal - February 2015 information
-
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE proposal paper February 2015
-
-
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - matrix of stakeholders
-
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - matrix of stakeholders (PDF 41 KB)
-
TA274 Macular oedema (diabetic) - ranibizumab: press release information
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination
-
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination guidance
-
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): consultee and commentator comments on the ACD
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis (PDF 189 KB)
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK (PDF 67 KB)
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB (PDF 28 KB)
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD (PDF 14 KB)
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS (PDF 108 KB)
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health (PDF 8.3 KB)
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): comments on the ACD received from the public through the NICE website
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation
-
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): evaluation report
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): pre-meeting briefing
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): pre-meeting briefing (PDF 86 KB)
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Evidence Review Group report for NICE rapid review
-
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis (PDF 299 KB)
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope
-
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope (PDF 28 KB)